Is Merck & Co. (MRK) a risky stock?
As of July 21, 2026, Clavix grades Merck & Co. (MRK) A for risk, a composite score of 89 out of 100 on an A+ to F scale, which puts MRK in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind MRK's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how MRK scores on each, as of July 21, 2026.
What's moving MRK's risk right now
Company-specific signals Clavix flags behind MRK's current grade, drawn from recent news and filings as of July 21, 2026.
Merck's Lipfendra just won FDA approval, making it the first pill in the PCSK9 cholesterol drug class. That gives Merck a first-mover edge over injectable rivals and could open a fresh revenue stream.
Merck's new once-daily pill Lipfendra offers a more convenient option than injectable PCSK9 drugs. As the first pill of its kind, it could help Merck tap a large pool of patients who aren't currently treated.
Merck priced its newly approved oral PCSK9 pill Lipfendra at $315 per month, putting it up against injectable incumbents like Amgen's Repatha. The first-in-class pill gives patients a shot-free alternative.
What a A grade means
On the Clavix A+ to F scale, MRK's composite of 89 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell MRK or any security. Grades are risk indicators, not predictions of return. Data may be delayed.